Intraductal papillary mucinous neoplasm of pancreas: Clinicopathological features and long-term survival after surgical resection

Nasca, 2020, Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification, Int J Mol Sci, 21, 10.3390/ijms21176386 Kim, 2018, Precursor Lesions of Pancreatic Cancer, Oncol Res Treat, 41, 603, 10.1159/000493554 Basturk, 2019, Pancreatic intraductal papillary mucinous neoplasm, 310 Aronsson, 2017, Intraductal papillary mucinous neoplasm of the pancreas – epidemiology, risk factors, diagnosis, and management, Scand J Gastroneterol, 52, 803, 10.1080/00365521.2017.1318948 Lim, 2019, The diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas: has progress been made?, Updates Surg, 71, 209, 10.1007/s13304-019-00661-0 Sereni, 2019, Molecular and clinical patterns of local progression in the pancreatic remnant following resection of pancreatic intraductal papillary mucinous neoplasm (IPMN), Chin Clin Oncol, 8, 21, 10.21037/cco.2019.04.03 Marchegiani, 2015, Patterns of Recurrence After Resection of IPMN: Who, When, and How?, Ann Surg, 262, 1108, 10.1097/SLA.0000000000001008 Rodrigues, 2020, Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas, Pancreatology, 20, 722, 10.1016/j.pan.2020.03.009 Tanaka, 2012, International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas, Pancreatology, 12, 183, 10.1016/j.pan.2012.04.004 Tanaka, 2017, Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas, Pancreatology, 17, 738, 10.1016/j.pan.2017.07.007 Basturk, 2015, A Revised Classification System and Recommendations from the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas, Am J Surg Pathol, 39, 1730, 10.1097/PAS.0000000000000533 Adsay, 2016, Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting, Ann Surg, 263, 162, 10.1097/SLA.0000000000001173 Fritz, 2011, Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas, Br J Surg, 98, 104, 10.1002/bjs.7280 Bassi, 2017, The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After, Surgery, 161, 584, 10.1016/j.surg.2016.11.014 Wente, 2007, Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition, Surgery, 142, 20, 10.1016/j.surg.2007.02.001 Centers for Disease Control and Prevention. Surgical Site Infection [Internet]. Estados Unidos de Norte América: CDC 2018 [Accessed 02 September 2018]. Available in: https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf. Dindo, 2004, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, 240, 205, 10.1097/01.sla.0000133083.54934.ae Von Elm, 2014, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies, Int J Surg, 12, 1495, 10.1016/j.ijsu.2014.07.013 Schmidt, 2018, What is the Incidence of Malignancy in Resected IPMN? An Analysis of Over 100 U.S. Institutions in a Single Year, Ann Surg Oncol, 25, 1797, 10.1245/s10434-018-6478-6 Morales-Oyarvide, 2018, Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes, J Gastrointest Surg, 22, 226, 10.1007/s11605-017-3602-z Crippa, 2020, Review of the diagnosis and management of intraductal papillary mucinous neoplasms, United European Gastroenterol J, 8, 249, 10.1177/2050640619894767 Cortegoso Valdivia, 2018, Diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas, Acta Biomed, 89, 147 Tanaka, 2019, Clinical Management and Surgical Decision-Making of IPMN of the Pancreas, Methods Mol Biol, 1882, 9, 10.1007/978-1-4939-8879-2_2 Levink, 2018, Management of Intraductal Papillary Mucinous Neoplasms: Controversies in Guidelines and Future Perspectives, Curr Treat Options Gastroenterol, 16, 316, 10.1007/s11938-018-0190-2 Tanaka, 2021, Acute pancreatitis in intraductal papillary mucinous neoplasms correlates with pancreatic volume and epithelial subtypes, Pancreatology, 21, 138, 10.1016/j.pan.2020.11.005 Morales-Oyarvide, 2015, Acute pancreatitis in intraductal papillary mucinous neoplasms: A common predictor of malignant intestinal subtype, Surgery, 158, 1219, 10.1016/j.surg.2015.04.029 Kim, 2017, Diagnostic accuracy of diffusion restriction in intraductal papillary mucinous neoplasm of the pancreas in comparison with "high-risk stigmata" of the 2012 international consensus guidelines for prediction of the malignancy and invasiveness, Acta Radiol, 58, 1157, 10.1177/0284185116685921 Kamata, 2019, Endoscopic diagnosis of cystic lesions of the pancreas, Dig Endosc, 31, 5, 10.1111/den.13257 Ciprani, 2020, An elevated CA 19-9 is associated with invasive cancer and worse survival in IPMN, Pancreatology, 20, 729, 10.1016/j.pan.2020.04.002 Kim, 2015, Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas, J Hepatobiliary Pancreat Sci, 22, 699, 10.1002/jhbp.275 Wang, 2015, Serum carcinoembryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: A meta-analysis, Biomed Rep, 3, 43, 10.3892/br.2014.376 European Study Group on Cystic Tumours of the Pancreas, 2018, European evidence-based guidelines on pancreatic cystic neoplasms, Gut, 67, 789, 10.1136/gutjnl-2018-316027 Izumo, 2020, Importance of each high-risk stigmata and worrisome features as a predictor of high-grade dysplasia in intraductal papillary mucinous neoplasms of the pancreas, Pancreatology, 20, 95, 10.1016/j.pan.2020.06.011 Hirono, 2020, Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas, Surg Today, 50, 50, 10.1007/s00595-019-01931-5 Oyama, 2020, Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms, Gastroenterology, 158, 226, 10.1053/j.gastro.2019.08.032 Attiyeh, 2018, Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium, Ann Surg, 267, 157, 10.1097/SLA.0000000000002015 Gavazzi, 2022, Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival, Dig Liver Dis, 54, 826, 10.1016/j.dld.2021.06.006 Capretti, 2022, Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma, Pancreatology, 3 Kaiser, 2022, IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy, Eur J Surg Oncol, 48, 1309, 10.1016/j.ejso.2021.12.009